MBCProject_4634_T1_RNA
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.650
- MYC_TARGETS_V1+0.640
- MYC_TARGETS_V2+0.590
- G2M_CHECKPOINT+0.570
- MTORC1_SIGNALING+0.470
- SPERMATOGENESIS+0.420
- OXIDATIVE_PHOSPHORYLATION+0.380
- GLYCOLYSIS+0.350
- DNA_REPAIR+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.240
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- NOTCH_SIGNALING-0.410
- UV_RESPONSE_DN-0.410
- ESTROGEN_RESPONSE_EARLY-0.380
- ALLOGRAFT_REJECTION-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
- IL6_JAK_STAT3_SIGNALING-0.360
- INFLAMMATORY_RESPONSE-0.360
- IL2_STAT5_SIGNALING-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_MV6ASWV9 | ATRT | — | 0.919 |
| 2 | TCGA-XF-A9ST-01A-11R-A42T-07 | — | — | 0.919 |
| 3 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.917 |
| 4 | SRR975602 | — | — | 0.914 |
| 5 | BS_YBJBSRHV | Embryonal tumors | — | 0.912 |
| 6 | SRR8518376 | — | E | 0.912 |
| 7 | C3L-02649 | — | cohortMD1 | 0.911 |
| 8 | ERR2208894 | — | — | 0.909 |
| 9 | TCGA-66-2754-01A-01R-0980-07 | — | cohortA3 | 0.906 |
| 10 | MDT-AP-0134 | Med | Medulloblastoma | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.650 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.640 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.590 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.570 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.470 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.420 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.350 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.150 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| HYPOXIA | 0.020 | Idelalisib | — uncovered |